Showing 15 posts of 15 posts found.

BioIVT acquires PrecisionMed for neurology and oncology research

July 21, 2023
Sales and Marketing Neurology, Oncology, neurology, oncology

BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …


Cartesian Therapeutics announces successful trial of RNA cell therapy in autoimmunity

June 23, 2023
Research and Development Cartesian Therapeutics, Neurology, RNA, autoimmune, neurology

Clinical stage biotechnology company, Cartesian Therapeutics, has announced results from its clinical trial using RNA CAR T (rCAR T) therapy …

Nido Biosciences raises $109m in funding for neurological diseases treatments

May 16, 2023
Sales and Marketing Financing, Neurology, Nido Biosciences, funding, neurology

US-based clinical-stage company Nido Biosciences has announced that is has received $109m in Seed, Series A and Series B financings, …

AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD

May 11, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology

AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …


FDA approves MS drug for human trials

January 27, 2020
Sales and Marketing MS, MS symptoms, MS treatment, Neuro, neurology

A drug that can make it easier to diagnose Multiple Sclerosis (MS) has been approved for its first human trials …


British scientist develops technology able to deliver drugs directly into the brain

February 27, 2019
Research and Development device, medical technology, neurology, neuroscince, parkinson's cns

A British scientist has developed innovative technology that is able to deliver drugs deep into the brain in order to …


Vitamin D deficiency may cause cognitive decline through weakening brain’s scaffolding

February 26, 2019
Manufacturing and Production NPP, mental health, neurology, neuroscience, schizophrenia, vitamin d

Vitamin D deficiency may weaken supportive ‘scaffolding’ in the brain thus causing neurons difficulty in maintaining connections, according to a …


Mayor of London announces Takeda, UCL R&D partnership

October 14, 2015
Research and Development London, R&D, Takeda, UCL, neurology

Takeda is teaming up with researchers at University College London (UCL) to identify and validate novel target genes for the …

Alzheimer's research

Neurimmune kicks off late-stage Alzheimer’s study

September 9, 2015
Research and Development Alzheimer's disease, Biogen, Neurimmune, aducanumab, neurology

Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab.  The …


Neurology comes to the fore

September 7, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology

Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …

Alzheimer's brain

Amgen and Novartis partner on Alzheimer’s and migraine treatments

September 2, 2015
Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience

Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine.  The companies plan …

Teva image

Teva bolsters neurology unit through Auspex deal

March 31, 2015
Sales and Marketing CNS, SD-809, Teva, Tourette syndrome, auspex, deutetrabenazine, neurology

Teva is significantly enhancing its neurology business by acquiring US biopharma firm Auspex in a deal worth $3.5 billion. Teva …

biogen idec image

Biogen signs neurology deal

September 11, 2013
Research and Development, Sales and Marketing Biogen IDEC, Isis, antisense, neurology

Biogen Idec and Isis Pharmaceuticals have entered their fourth partnership in two years in a deal that will see the …

syntaxin image

Ipsen buys Syntaxin

July 16, 2013
Research and Development, Sales and Marketing R&D, ipsen, neurology, syntaxin, tsi

French pharma group Ipsen has snapped up privately-owned UK life sciences firm Syntaxin for an upfront payment of €28 million …

UCB signs Parkinson’s research deal

October 12, 2010
Research and Development Parkinson's, Synosia Therapeutics, UCB, neurology

UCB has partnered with Synosia Therapeutics to develop two of the Swiss firm’s compounds for Parkinson’s disease.  Basel-based Synosia has …

Latest content